Gabriel Liberatore

Group Chief Operating Officer. Non-Exec Director. Passion for working at the interface between life-changing medical science and business

[Gabriel Liberatore @GabLiberatore]

Looking forward to working closely with CLSA and Carche on GlyTherix Ltd Pre-Initial Public Offering (IPO) raise. Stay tunned for exciting news shortly.

#Glytherix #radiopharmaceuticals #theranostics #capitalraise https://t.co/eOT9xSrIiK

[Gabriel Liberatore @GabLiberatore]

Glypican-1 (GPC-1), the basis for GlyTherix's proprietary antibody Miltuximab® is certainly an interesting and novel target for solid tumours. GlyTherix are investigating multiple mechanisms of action including radioimmunotherapy, bi-specific antibodies…https://t.co/3ZGploZwBf

[Gabriel Liberatore @GabLiberatore]

Great coverage from Mergermarket!

#Glytherix #radiopharmaceuticals #preIPO #theranostics #immunooncology https://t.co/XbylcNoisy

[CommBank Socceroos @Socceroos]

WE'RE INTO THE #FIFAWORLDCUP ROUND OF 16!!!

🇦🇺🇦🇺🇦🇺🇦🇺🇦🇺🇦🇺🇦🇺🇦🇺🇦🇺🇦🇺🇦🇺🇦🇺🇦🇺🇦🇺🇦🇺🇦🇺🇦🇺

#GiveIt100 #Socceroos

[Telix Pharmaceuticals @TelixPharma]

Telix has acquired Optimal Tracers, a Sacramento-based radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials.

We look forward to welcoming OT into the Telix family!

https://t.co/P9lAzMr2X4

[Telix Pharmaceuticals @TelixPharma]

Telix is pleased to today announce that the pivotal Phase III ZIRCON study of its investigational kidney cancer imaging agent TLX250-CDx has met its co-primary and key secondary endpoints, exceeding targets for sensitivity and specificity.

More here: https://t.co/MLI8FgbJCm

[Prof Andrew Scholey PhD @Scholey]

Highly, highly recommended This should be compulsory reading for every PhD student, supervisor, postgrad administrator, dean - and pretty much anyone in academia! Shout-out to @ZJAyres

[Gabriel Liberatore @GabLiberatore]

Well done to all involved!

#telixpharma #radiopharmaceuticals #UQ #ARC https://t.co/Rr5Fbbp5zV

[Gabriel Liberatore @GabLiberatore]

@biomelb @DrEmmaBall @illumina Congrats @DrEmmaBall

[Gabriel Liberatore @GabLiberatore]

#TelixPharma #Theranostics #RenalCancer #KidneyCancer #TLX250 https://t.co/gyxd7xgsNT

[Gabriel Liberatore @GabLiberatore]

https://t.co/892pHKsBRW

[Telix Pharmaceuticals @TelixPharma]

We are pleased to announce a licence agreement with @LillyPad, granting Telix exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly’s #olaratumab antibody, for diagnosing and treating human cancers.

More on our website: https://t.co/K69Ssyvf3t

[Gabriel Liberatore @GabLiberatore]

#TelixPharma #SeeItTreatIt #Lilly #Olaratumab https://t.co/6fvokiQxsM

[Telix Pharmaceuticals @TelixPharma]

Together with GMS Australia and @MonashUni, we are pleased to announce $23M Government funding as part of $71M Australian Precision Medicine Enterprise (APME) project to enable production of theranostic radiopharmaceuticals in the APAC region.

More here: https://t.co/kzBIwOw6bl

[Gabriel Liberatore @GabLiberatore]

https://t.co/wj55N3Z7eY

[Gabriel Liberatore @GabLiberatore]

https://t.co/KZBME8xE2S

[Gabriel Liberatore @GabLiberatore]

#TelixPharma #seeittreatit #TLX66 #ODD #HSCT #BMC https://t.co/D3wYnRpzcW

[Gabriel Liberatore @GabLiberatore]

https://t.co/z6Rg8fOobB

[Gabriel Liberatore @GabLiberatore]

Career guidance to PhD students is extremely important. @_IMNIS not only benefits the mentee but also gives the mentor the opportunity to contribute to our community, the #STEM ecosystem and to help, in-part, foster the next generation of STEM professionals #proudIMNISMentor

[IMNIS @_IMNIS]

#MentorMonday is Dr Gabriel Liberatore (@GabLiberatore). Gabriel is the Group Chief Operating Officer at Telix Pharmaceuticals and has 20 years experience in senior operational, business development and R&D management positions. Gabriel has been a #proudIMNISMentor since 2017.

[Gabriel Liberatore @GabLiberatore]

https://t.co/HWHPuE2UWT